Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Share

Review
.2010 Jun;62(2):265-304.
doi: 10.1124/pr.108.000992. Epub 2010 Apr 14.

Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery

Affiliations
Review

Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery

Terry Kenakin et al. Pharmacol Rev.2010 Jun.

Abstract

It is useful to consider seven transmembrane receptors (7TMRs) as disordered proteins able to allosterically respond to a number of binding partners. Considering 7TMRs as allosteric systems, affinity and efficacy can be thought of in terms of energy flow between a modulator, conduit (the receptor protein), and a number of guests. These guests can be other molecules, receptors, membrane-bound proteins, or signaling proteins in the cytosol. These vectorial flows of energy can yield standard canonical guest allostery (allosteric modification of drug effect), effects along the plane of the cell membrane (receptor oligomerization), or effects directed into the cytosol (differential signaling as functional selectivity). This review discusses these apparently diverse pharmacological effects in terms of molecular dynamics and protein ensemble theory, which tends to unify 7TMR behavior toward cells. Special consideration will be given to functional selectivity (biased agonism and biased antagonism) in terms of mechanism of action and potential therapeutic application. The explosion of technology that has enabled observation of diverse 7TMR behavior has also shown how drugs can have multiple (pluridimensional) efficacies and how this can cause paradoxical drug classification and nomenclatures.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Typical topology of 7TMRs. Shown is a representative structure of a family A 7TMR with a peptide ligand. The extracellular ectodomain is shown in the top of the lateral views, whereas the top views provide appreciation for the helical bundle domain. The cytosolic region is shown at the bottom of the lateral views. The transmembrane segments are colored blue to red from amino terminus toward carboxyl terminus of the receptor. Shown at the carboxyl-terminal end of TM7 is the extension into another helix 8 that lies adjacent to the cytosolic face of the lipid bilayer.
Fig. 2.
Fig. 2.
Allosteric systems. Energy is transmitted between loci of binding for the modulator and that of the guest. Energy transfer is reciprocal (Tränkle et al., 1999); therefore, the role of modulator and guest are operationally interchangeable. For an extracellular modulator binding site, the guest binding site can be extracellular, within the plane of the membrane, or facing the cytosol.
Fig. 3.
Fig. 3.
Two proposed modes of allostery. The allosteric “hot wire” proposes a preferred energy link between an allosteric binding site and the guest site; in the past, this has been an assumed mechanism. Global allosteric modulation predicts that changes at the guest allosteric site are part of global conformational variations within an ensemble of conformations.
Fig. 4.
Fig. 4.
Classification of allostery on the basis of number of sites. A, multiple site allostery involves the interaction of more than one guest with the modulator. Probe dependence results in different effects on each guest for a given modulator. The example shown shows the effect of the CCR5 modulator aplaviroc on CCL5 (no effect on binding) and HIV-1 (complete inhibition of binding) (Watson et al., 2005). B, probe dependence can also result from the interaction of different modulators at the same modulator binding site for the same guest. The different abilities of alkyltrimethylammonium compounds to initiate contraction of guinea pig ileum as mediated by G protein binding is a classic example (Stephenson, 1956). Both the modulator(s) and G proteins bind at a single site.
Fig. 5.
Fig. 5.
The vectorial nature of 7TMR allostery. Modulators can affect binding and function of other ligands cobinding to the receptor (classic guest allostery); of the cobinding of other proteins along the plane of the membrane (other receptors or membrane-binding proteins such as RAMPs); or of cytosolic signaling proteins, such as G proteins or β-arrestin. These effects can be simultaneous and all emanate from the same mechanism(s) of allosteric change within the conduit 7TMR protein.
Fig. 6.
Fig. 6.
Basic model for allosteric interaction of a modulator (A or B) interacting with a receptor (R) to affect the interaction of a guest (counterpart A or B). If A is an agonist, then agonism can emanate from the species AR and/or the allosterically modified species ARB. The modulator would then be B, which can affect the affinity of the agonist for the receptor (through α) or the efficacy of the receptor (relative efficacy of the species ARB/AR described as β). This can result in a range of new responses to ligand A from potentiation to antagonism. The binding species are from the model given by Ehlert (1988); the response components can be added through melding of that model with the operational model for receptor function (Black and Leff, 1983) to yield a general functional model of allosteric 7TMR function (Ehlert, 2005; Kenakin, 2005; Price et al., 2005).
Fig. 7.
Fig. 7.
Two types of allosteric system derived from receptor oligomers. A, the receptor dimer becomes a completely new conduit and ligands interact through this new conduit with revised interactive behaviors. For example, the dopamine antagonists quinpirole and sulpiride bind to a somatostatin SSTR5-dopamine receptor D2 heterodimer to block the binding of somatostatin (Rocheville et al., 2000). B, another receptor (or membrane bound protein such as RAMP) becomes the modulator that confers new reactivity toward a guest through a receptor. For example, the bradykinin-2 receptor can act as a modulator and bind to the angiotensin1 receptor to change the binding characteristics of angiotensin-1 (AbdAlla et al., 2000).
Fig. 8.
Fig. 8.
Two contrasting mechanisms of receptor antagonism. A, orthosteric antagonists block agonist activation of the receptor and all functions mediated by that activation are uniformly inhibited. For example, prostaglandin D2 is the endogenous agonist for CRTH2 receptors causing activation of Gαs protein and β-arrestin. An orthosteric antagonist blocking PDG2 binding to the receptor would block both pathways. B, the allosteric modulatorN-α-tosyltryptophan (N-α-T) blocks the Gαs protein activation of CRTH2 through PDG2 but still allows the agonist to active β-arrestin (Mathiesen et al., 2005).
Fig. 9.
Fig. 9.
Differences in relative agonist activity with changes in cellular background. A, calcium transient response for activation of human calcitonin receptors transfected into HEK293 cells by eel (●), porcine (○), and rat (▴) calcitonin and rat amylin (▵). B, responses to the same agonists in HEK293 cells transfected with Gαs protein. Note that the relative potencies of the agonists change. The table shows the activity of the agonists in terms of their log transduction ratios [Log (τ/KA)] values in the two cell hosts and their relative activity in terms of the reference agonist amylin [ΔLog(τ/KA) values]. A measure of the relative effect of Gαs-transfection on each agonist is given as the bias. Data from Watson et al. (2000).
Fig. 10.
Fig. 10.
Biased agonism at the angiotensin II receptor. The natural ligand angiotensin II produces activation of G proteins, which can produce a deleterious pressor response in hypertension and heart failure and also stimulates β-arrestin to initiate ERK, Akt, and phosphatidylinositol 3-kinase signals, which could be cytoprotective. The biased agonist SII produces only activation of β-arrestin to induce cytoprotection but not pressor response. Moreover, receptor occupancy of the receptor by SII prevents activation by endogenous angiotensin (the receptor is blocked), thereby further protecting against endogenous pressor response. Data from Violin and Lefkowitz (2007).
See this image and copyright information in PMC

Similar articles

  • Histology, Axon.
    Muzio MR, Fakoya AO, Cascella M.Muzio MR, et al.2022 Nov 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.2022 Nov 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.PMID:32119275Free Books & Documents.
  • Unraveling GPCRs Allosteric Modulation. Cannabinoid 1 Receptor as a Case Study.
    Cruz A, Warshel A.Cruz A, et al.Proteins. 2025 Apr;93(4):763-785. doi: 10.1002/prot.26762. Epub 2024 Nov 25.Proteins. 2025.PMID:39584635
  • Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.
    Salisbury L, Baraitser L.Salisbury L, et al.In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5.In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5.PMID:36137063Free Books & Documents.Review.
  • The 2023 Latin America report of theLancet Countdown on health and climate change: the imperative for health-centred climate-resilient development.
    Hartinger SM, Palmeiro-Silva YK, Llerena-Cayo C, Blanco-Villafuerte L, Escobar LE, Diaz A, Sarmiento JH, Lescano AG, Melo O, Rojas-Rueda D, Takahashi B, Callaghan M, Chesini F, Dasgupta S, Posse CG, Gouveia N, Martins de Carvalho A, Miranda-Chacón Z, Mohajeri N, Pantoja C, Robinson EJZ, Salas MF, Santiago R, Sauma E, Santos-Vega M, Scamman D, Sergeeva M, Souza de Camargo T, Sorensen C, Umaña JD, Yglesias-González M, Walawender M, Buss D, Romanello M.Hartinger SM, et al.Lancet Reg Health Am. 2024 Apr 23;33:100746. doi: 10.1016/j.lana.2024.100746. eCollection 2024 May.Lancet Reg Health Am. 2024.PMID:38800647Free PMC article.Review.
  • Far Posterior Approach for Rib Fracture Fixation: Surgical Technique and Tips.
    Manes TJ, DeGenova DT, Taylor BC, Patel JN.Manes TJ, et al.JBJS Essent Surg Tech. 2024 Dec 6;14(4):e23.00094. doi: 10.2106/JBJS.ST.23.00094. eCollection 2024 Oct-Dec.JBJS Essent Surg Tech. 2024.PMID:39650795Free PMC article.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. AbdAlla S, Lother H, Quitterer U. (2000) AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407:94–98 - PubMed
    1. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, et al. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2:95–102 - PubMed
    1. Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ. (2003) Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 100:1740–1744 - PMC - PubMed
    1. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ. (2004) Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279:35518–35525 - PubMed
    1. Akam EC, Challiss RA, Nahorski SR. (2001) Gq/11 and Gi/1o activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype. Br J Pharmacol 132:950–958 - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp